Interestingly, Calvo et al. (2011) found that RASGRF2 could prevent Cdc42 activation, thus inhibiting Cdc42-mediated cellular processes, including transformation, cytoskeletal dynamics, and tumor cell motility. Here, CDC42 is linked to neoplasm.